A Cross-sectional Study to Investigate the Effect of Topiramate on Bone and Mineral Metabolism in Female Participants With Epilepsy
A Cross-sectional, Comparative, Multi-center Study to Investigate the Effect of Topiramate Monotherapy on Markers of Bone Mineral Metabolism and Bone Mineral Density in Premenopausal Women With Epilepsy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Participants who agree to participate in this study
- Female epileptic participants
- Participants who are receiving topiramate, carbamazepine or valproic acid monotherapy for more than one year
- Participants who are using proper contraceptive method (s) or have a negative pregnancy test result
Exclusion Criteria:
- Participants with a motor function disorder
- Participants with a disease which affects their skeleton including primary hyperparathyroidism, Paget's disease, multiple myeloma, liver and kidney disorder, thyroid disease, malabsorption disorder, diabetes, and malignancies
- Participants who have taken within last one year, or are currently taking a drug which affects the bone and mineral metabolism such as vitamin D, calcium, anabolic steroids, bisphosphonates, calcitonin, glucocorticoids, and diuretics
- Voluntary or surgical postmenopausal participants
- Participants with amenorrhea for more than 6 months
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Topiramate
Female participants with epilepsy will be observed, who were receiving topiramate for more than one year.
|
This is an observational study.
Female participants with epilepsy will be observed, who were receiving topiramate for more than one year.
|
|
Carbamazepine
Female participants with epilepsy will be observed, who were receiving carbamazepine for more than one year.
|
This is an observational study.
Female participants with epilepsy will be observed, who were receiving carbamazepine for more than one year.
|
|
Valproic acid
Female participants with epilepsy will be observed, who were receiving valproic acid for more than one year.
|
This is an observational study.
Female participants with epilepsy will be observed, who were receiving valproic acid for more than one year.
|
|
Normal Control
Healthy female participants will be observed in Normal control group.
|
This is an observational study.
Healthy female participants will be observed in Normal control group.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Absolute Concentration of Calcium in Serum and Random Urine
Time Frame: 24 hours
|
Bone and mineral metabolic marker represents the structure, cyclical metabolism, and hormone regulation of bone.
Urinary calcium is one of the indicators of bone resorption (bone loss due to osteoclastic activity).
Absolute concentration of calcium in serum and random urine will be assessed.
|
24 hours
|
|
Absolute Concentration of 25-hydroxy Vitamin D, Osteocalcin, Carboxy-terminal Telopeptide of type 1 collagen (CTx) and Somatomedin-C (IGF-1) in Serum
Time Frame: 24 hours
|
Osteocalcin is a vitamin K-dependent calcium-binding protein synthesized by osteoblasts and found primarily in bones.
Serum osteocalcin measurements provide a noninvasive specific marker of bone metabolism.
CTx is marker for bone resorption (bone loss due to osteoclastic activity).
IGF-1 has growth-regulating, insulin-like, and mitogenic activities.
Absolute concentration of 25-hydroxy vitamin D, osteocalcin, carboxy-terminal telopeptide of type 1 collagen (CTx) and somatomedin-C (IGF-1) in serum will be assessed.
|
24 hours
|
|
Absolute Concentration of 1-alpha 25-dihydroxyvitamin D-3, Parathyroid Hormone (PTH) in Serum
Time Frame: 24 hours
|
Bone and mineral metabolic marker represents the structure, cyclical metabolism, and hormone regulation of bone.
1-alpha 25-dihydroxyvitamin D-3 (vitamin D-3) and Parathyroid hormone (PTH) were assessed.
The PTH maintains intracellular calcium levels in the body.
|
24 hours
|
|
Absolute Concentration of Bone-specific Alkaline Phosphatase (BSAP) in Serum
Time Frame: 24 hours
|
Bone and mineral metabolic marker represents the structure, cyclical metabolism, and hormone regulation of bone.
Bone-specific alkaline phosphatase (BSAP) reflects formation of organic matrix in bone.
Absolute concentration of BSAP in Serum will be assessed.
|
24 hours
|
|
Absolute Concentration of Bicarbonate in Serum
Time Frame: 24 hours
|
Bicarbonate levels in the blood are an index of the alkali reserve or buffering capacity.
Difference in Bicarbonate level between topiramate, carbamazepine and valproic acid monotherapy groups will be assessed.
|
24 hours
|
|
Absolute Concentration of Calcium in Urine in 24 Hours
Time Frame: 24 hours
|
Absolute concentration of calcium in urine will be examined by urine test.
|
24 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Spine, Total hip and Femoral Neck Z-Score
Time Frame: 24 hours
|
Z-score is number of standard deviations a participant's bone mineral density (BMD) differs from the average BMD of their age, sex, and ethnicity.
Positive scores indicate BMD above the mean; Positive values are "best values" and negative values are "worst values".
Z-score will be evaluated for spine, hip and femoral neck.
|
24 hours
|
|
Percentage of Participants With Osteopenia and Osteoporosis Based on Spine T-score
Time Frame: 24 hours
|
Osteoporosis means reduction of bone mass without alteration in the composition of bone, leading to fractures.
Osteopenia is a metabolic bone disease.
The T-score is a radiographic diagnosis that compares bone mineral density (BMD) to that of a "normal, healthy, 30-year-old female".
The lower the T-score, the lower the BMD.
A T-score of +1 to -1 is normal.
A T-score decrease of -1 indicates a 10%-15% decrease in BMD.
Percentage of participants with osteopenia and osteoporosis based on spine T-score will be assessed.
|
24 hours
|
|
Percentage of Participants With Osteopenia and Osteoporosis Based on Spine Z-score
Time Frame: 24 hours
|
Osteoporosis means reduction of bone mass without alteration in the composition of bone, leading to fractures.
Osteopenia is a metabolic bone disease.
The Z-score is number of standard deviations a participant's bone mineral density (BMD) differs from the average BMD of their age, sex, and ethnicity.
Positive scores indicate BMD above the mean; Positive values are "best values" and negative values are "worst values".
Z-score will be evaluated for spine, hip and femoral neck.
Percentage of participants with osteopenia and osteoporosis based on spine Z-score will be assessed.
|
24 hours
|
|
Absolute Concentration of Phosphorus and Creatinine in Random Urine
Time Frame: 24 hours
|
Absolute concentration of phosphorus and creatinine in urine will be examined by urine test.
|
24 hours
|
|
Absolute concentration of Sodium in Random Urine
Time Frame: 24 hours
|
Absolute concentration of sodium in urine will be examined by urine test.
|
24 hours
|
|
Absolute Concentration of Phosphorus and Creatinine in 24 Hour Urine
Time Frame: 24 hours
|
Absolute concentration of phosphorus and creatinine in 24 hour urine will be examined by urine test.
|
24 hours
|
|
Absolute concentration of Sodium in 24 Hour Urine
Time Frame: 24 hours
|
Absolute concentration of sodium in 24 hour urine will be examined by urine test.
|
24 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Janssen Korea, Ltd. Clinical Trial, Janssen Korea, Ltd., Korea
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Musculoskeletal Diseases
- Bone Diseases
- Epilepsy
- Seizures
- Osteoporosis
- Bone Diseases, Metabolic
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Tranquilizing Agents
- Psychotropic Drugs
- Membrane Transport Modulators
- GABA Agents
- Anticonvulsants
- Sodium Channel Blockers
- Antimanic Agents
- Cytochrome P-450 Enzyme Inducers
- Cytochrome P-450 CYP3A Inducers
- Valproic Acid
- Carbamazepine
- Topiramate
Other Study ID Numbers
Other Study ID Numbers
- CR015856
- TOP-KOR-31
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.